The present disclosure provides crystalline polymorphic and amorphous forms of (R)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 1) or (S)-3,5-dimethyl-benzoic acid N-(1-tert-butyl-butyl)-N'-(2-ethyl-3-methoxy-benzoyl)-hydrazide (Compound 2). The present disclosure further provides compositions comprising crystalline polymorphic and amorphous forms of Compound 1 or Compound 2 and an excipient, methods of making crystalline polymorphic or amorphous forms of Compound 1 or Compound 2, and methods of using crystalline polymorphic or amorphous forms of Compound 1 or Compound 2 to regulate gene expression in a cell or in a subject.本發明提供結晶狀多晶形式和非晶形式之(R)-3,5-二甲基-苯甲酸N-(1-第三丁基-丁基)-N'-(2-乙基-3-甲氧基-苯甲醯基)-醯肼(化合物1)或(S)-3,5-二甲基-苯甲酸N-(1-第三丁基-丁基)-N'-(2-乙基-3-甲氧基-苯甲醯基)-醯肼(化合物2)。本發明進一步提供包含結晶狀多晶形式和非晶形式之化合物1或化合物2及賦形劑之組成物，製造結晶狀多晶形式和非晶形式之化合物1或化合物2之方法，及使用結晶狀多晶形式和非晶形式之化合物1或化合物2以調節細胞中或個體中的基因表現之方法。
